rhEPO Market in China 2016-2020

rhEPO Market in China 2016-2020

Category : Medical Devices
Sub Category : General Medical Device
Published On : June  2016
Pages : 65

------------ Or -------------
About the Recombinant Human Erythropoietin (rhEPO) Market in China
Erythropoietin (EPO), also referred to as hematopoietin or hemopoietin, is a glycoprotein responsible for producing erythrocytes in the body. In the fetal stage, this protein is produced in the liver; it is secreted by the kidneys in adulthood. During anemic conditions, the body produces an excess of EPO, maintaining the inormal levels of red blood cells (RBC). When the endogenous production of EPO is disturbed because of diseases or the use of medications, the inormal RBC levels can be maintained by an external supply of EPO-stimulating agents (ESAs). These agents are similar to the inatural EPO in structure and function and are administered as injections. They can be produced by recombinant DNA technology and are used to treat anemia due to kidney diseases, cancer, HIV, injuries, or neural diseases. 
Technavio’s analysts forecast the recombinant human erythropoietin (rhEPO) market in China to grow at a CAGR of 16.89% during the period 2016-2020.
Covered in this report 
The report covers the present scenario and the growth prospects of the recombinant human erythropoietin (rhEPO) market in China for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and biosimilars used for the treatment of anemia due to renal diseases, cancer chemotherapy, antiretroviral therapy, and wounds and neural diseases. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period. 
The market is divided into the following segments based on application of rhEPO: 
• End-stage renal disease (ESRD)
• Cancer
• Human immunodeficiency virus (HIV)
• Wounds and neural disease
Technavio's report, Recombinant Human Erythropoietin (rhEPO) Market in China 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the operating in this market. 
Key vendors 
• 3S Bio
• Shanghai Chemo
• Chengdu Di’ao 
• NCPC Genetech 
• Kyowa Hakko Kirin
• Shandong Kexing
Other prominent vendors
• Ahua Pharmaceutical 
• Biosidus
• Dragon Pharma 
• Huaxin High Biotechnology 
• Kehua Bio-Engineering
• LG Life Sciences
• Shenzhen Sai Bao Er Bio-Pharmaceutical 
• Sihuan
• Shenyang Sunshine Pharmaceutical
• Uni-Bio Science Group 
• Wanbang Biochemical Pharmaceuticals
Market driver 
• Increase in chronic kidney disease (CKD) and dialysis patient population 
• For a full, detailed list, view our report 
Market challenge 
• Complex manufacturing process
• For a full, detailed list, view our report 
Market trend 
• Exploitation of novel therapeutic areas
• For a full, detailed list, view our report 
Key questions answered in this report 
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors? 
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Erythropoietin: An overview
• Clinical uses of EPO
• Abusive uses of EPO
• Risks of EPO use

PART 06: Global erythropoietin market

PART 07: China: Country snapshot
• Social and economic conditions
• Healthcare reforms
• Healthcare infrastructure

PART 08: Opportunities for pharmaceutical vendors in China
• Major pharmaceutical vendors in China
• Opportunities for global and local vendors

PART 09: Biopharmaceutical market in China
• Biosimilar market in China
• Market size and forecast

PART 10: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 11: Market segmentation by end-user
• Hospitals
• Retail pharmacies

PART 12: Market segmentation by application
• Cancer
• Wounds and neural disease

PART 13: Drug pricing and reimbursement in China
• Market-driven drug pricing strategy
• Scrutinization of illegal pricing of drugs

PART 14: Pipeline portfolio
• Uni-EPO-Fc

PART 15: Market drivers
• Increase in CKD and dialysis patient population
• Growth in prevalence of cancer
• Support for local manufacturers

PART 16: Impact of drivers

PART 17: Market challenges
• Complex regulatory framework and approval process
• Complex manufacturing process
• Development of alternative therapies

PART 18: Impact of drivers and challenges

PART 19: Market trends
• Penetration of rhEPO drugs in grade I and II hospitals
• Exploitation of novel therapeutic areas
• Initiation of R&D activities by local/domestic vendors

PART 20: Vendor landscape
• Competitive scenario
• Market analysis 2015
• 3S Bio
• Shanghai Chemo
• Chengdu Di'ao
• NCPC Genetech
• Kyowa Hakko Kirin
• Shandong Kexing
• Other prominent vendors

PART 21: Appendix
• List of abbreviations

PART 22: Explore Technavio

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Historical timeline of EPO development
Exhibit 03: Globally approved EPO biosimilars
Exhibit 04: China GDP 2010-2014 ($ trillions)
Exhibit 05: China: Healthcare expenditure 2009-2013 (% of GDP)
Exhibit 06: Healthcare reforms in China
Exhibit 07: China pharmaceutical market overview: SWOT analysis
Exhibit 08: New drug approval (NDA) review process in China
Exhibit 09: New drug approval process in China
Exhibit 10: Drug registration classification and requirements in China
Exhibit 11: Notable achievements in biopharmaceutical industry in china
Exhibit 12: Biopharmaceutical market in China 2015-2020 ($ billions)
Exhibit 13: rhEPO market in China in global biopharmaceutical market 2015
Exhibit 14: rhEPO market in China 2015-2020 ($ millions)
Exhibit 15: Five forces analysis
Exhibit 16: rhEPO market in China by distribution channels 2015
Exhibit 17: Share of domestic rhEPO drugs in hospitals in China 2015
Exhibit 18: Changes in the drug pricing system before and after 2015 reforms
Exhibit 19: Pipeline portfolio: rhEPO market in China
Exhibit 20: Impact of drivers
Exhibit 21: Impact of drivers and challenges
Exhibit 22:S Bio: YoY revenue comparison of EPIAO 2014-2015 ($ millions)
Exhibit 23:SBio: Key takeaways
Exhibit 24: Shanghai Fosun: YoY revenue and growth rate of blood system products 2013-2015 ($ millions)
Exhibit 25: Shanghai Chemo: Key takeaways
Exhibit 26: Chengdu Di'ao: Key takeaways
Exhibit 27: NCPC Genetech Biotechnology: Key takeaways
Exhibit 28: Kyowa Hakko Kirin: Key takeaways
Exhibit 29: Shandong Kexing: Key takeaways

Enquiry Before Buy